Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. reports developments for a commercial pharmaceutical business that markets differentiated products primarily in oncology. Company updates focus on product sales, commercial execution, portfolio changes, and financial results for its single reportable segment, including activity tied to Rolvedon and other branded pharmaceutical assets.
Recent announcements also cover capital-structure and corporate governance matters, material agreements, shareholder-related processes, and completed portfolio transactions. Assertio has reported the sale of U.S. rights to several branded products, including INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, and OTREXUP, while continuing to frame its commercial strategy around oncology-focused products.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.